Lindsley and colleagues (5) reported an antigen assay for diagnosis of histoplasmosis. Although they do not claim to have compared their test to that at MiraVista Diagnostics (9) , the reader may draw that conclusion since the authors note that I provided antibodies, vaccine strain, and patient specimens for their study (5) . They reported superior results using their antibodies.
They did not compare their assay to the MiraVista Diagnostics assay, however. The antibodies that I provided them in 1991 were from rabbits used in our original assay (2, 8) . The urine specimens were from patients with AIDS and progressive disseminated histoplasmosis (PDH) collected in 1983 to 1989, some of which were concentrated. Our original assay and those antibodies are now obsolete. In 2003, we discovered falsepositive results caused by antirabbit antibodies (7) . Subsequently we developed a second-generation assay that reduced false positivity by 75% (9) .
The authors imply that false-positive results caused by antirabbit antibodies would not be relevant in urine. False Legionella antigenuria was reported in a transplant patient treated with anti-thymocyte globulin (1), and we have observed false Histoplasma antigenuria in a myeloma patient. In that case, the urine was highly positive in our original assay but negative in our second-generation assay. That urine also contained antirabbit antibodies.
False antigenemia or antigenuria is not a trivial problem. Kricka concluded "Efforts should be directed at improving methods for identifying and eliminating this type of analytical interference (3)" and that "manufacturers of immunoassay test kits. . .must be agreed to. . .refinements of immunoassays to render them interference free (4) ." Use of an inferior test may lead to preventable testing errors.
What's less appreciated is the enhanced sensitivity of our second-generation assay. Improved sensitivity is desirable because false-negative results occurred in 20% of non-AIDS patients with PDH and two-thirds with pulmonary histoplasmosis (2, 10). We have produced antibodies that detect purified Histoplasma galactomannan with two-to fourfoldhigher sensitivity than our original antibodies. Sensitivity in patients also is superior. Among patients with AIDS and PDH (6), antigenuria was detected in 100% of patients in our second-generation assay versus 94% in our original assay and antigenemia was detected in 95% versus 87% (P ϭ 0.014), respectively (Fig. 1) . Furthermore, 15 of 18 (83%) serum specimens and 24 of 33 (73%) urine specimens, including baseline specimens or ones obtained during treatment, that were negative in the original assay were positive in the second-generation assay.
Comparison of their findings (5) to ours (Fig. 1) shows the two assays differ greatly. For example, their positive results in FIG. 1 . Histoplasma antigen in the original versus the second-generation MiraVista assay in AIDS patients with PDH. The left panel shows antigen in the baseline serum (n ϭ 36) and urine (n ϭ 38) specimens. Results for individual cases are connected by the diagonal lines, and points above the horizontal line at 1 unit (EU) are positive. The median antigen level in serum was 5.7 EU (95% confidence interval [CI], 2.4 to 11.6 EU) in the original versus 39.7 EU (95% CI, 19.9 to 50.5 EU) in the second-generation assay, and in urine, the level was 11.7 EU (95% CI, 9.2 to 12.9 EU) in the original versus 51.4 EU (95% CI, 42.5 to 58.5 EU) in the second-generation assay. The right panel shows antigen in serum (n ϭ 18) and urine (n ϭ 33) specimens obtained at enrollment or during therapy that were negative in the original assay (vertical axis from 0.1 to 10 EU because all results are Ͻ10 EU).
AIDS patients with PDH ranged from 1.4 to about 3.5 times their normal control. Positive results are always at least twice and often (ϳ30%) Ͼ100 times the normal control in our assay. Furthermore, specificity was not assessed in their assay but is about 98% in our assay, excluding other endemic mycoses. In summary, the recently reported Histoplasma antigen assay (5) has not been compared to the MiraVista assay (9) but appears to be less sensitive.
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